Denosumab versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis
posted on 2020-06-02, 09:57authored byShang-Yi Huang, Sung-Soo Yoon, Kazuyuki Shimizu, Wee Joo Chng, Cheng-Shyong Chang, Raymond Siu Ming Wong, Seasea Gao, Yang Wang, Steve W. Gordon, Anthony Glennane, Chang-Ki Min
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).